From Bench to Bedside: Material Selection and Clinical Translation of Nanocarrier Systems for Anticancer Drug Delivery

Hongyuan Yang

doi:10.54254/2753-8818/2025.AU28679

Theoretical and Natural ScienceOpen access

From Bench to Bedside: Material Selection and Clinical Translation of Nanocarrier Systems for Anticancer Drug Delivery

Research Article

Open Access

From Bench to Bedside: Material Selection and Clinical Translation of Nanocarrier Systems for Anticancer Drug Delivery

Hongyuan Yang ^1*

¹ HD Qingdao Wanda School

^*Corresponding author: 13376472855@163.com

Published on 28 October 2025

TNS Vol.147

ISSN (Print): 2753-8826

ISSN (Online): 2753-8818

ISBN (Print): 978-1-80590-489-2

ISBN (Online): 978-1-80590-490-8

Download Cover

Abstract

This study examines how material selection governs the design, performance, and clinical translation of nanocarrier systems for anticancer drug delivery. By comparatively analyzing organic (e.g., liposomes, polymeric micelles, protein-based carriers) and inorganic platforms (e.g., gold nanoparticles, mesoporous silica, carbon-based materials), we delineate how biocompatibility, drug‐loading mechanisms, surface chemistry, and stimuli responsiveness shape pharmacokinetics, tumor accumulation, and release profiles. We highlight design rules that connect physicochemical parameters—size, charge, morphology, and ligand density—to biological outcomes such as enhanced permeability and retention, receptor-mediated uptake, and intracellular trafficking. Beyond single-material systems, we evaluate hybrid and core–shell architectures that integrate complementary strengths (biodegradability, structural robustness, imaging/theranostic capability) to enable controlled, site-specific delivery and real-time monitoring. Translational considerations—including scalable synthesis, Good Manufacturing Practice readiness, batch-to-batch quality attributes, and safety/clearance pathways—are discussed as co-equal constraints with efficacy. This paper maps these considerations to clinical use-cases, noting where liposomes remain the regulatory benchmark, polymers offer programmable targeting and release, and inorganic or hybrid constructs unlock multifunctional therapies (photothermal, photoacoustic, or immuno-combination regimens). Finally, the author outlines a decision framework that aligns tumor biology (biomarkers, microenvironment, prior resistance) with nanocarrier typology to support personalized medicine. Collectively, the analysis provides practical guidance for matching material classes to therapeutic objectives, accelerating the trajectory from bench formulation to bedside impact in oncology.

Keywords:

Nanocarrier, Anticancer Drugs, Material Selection, Targeted Delivery, Side Effects

View PDF

References

[1]. Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014). Engineered Nanoparticles for Drug Delivery in Cancer Therapy. Angewandte Chemie International Edition, 53(47), 12620-12636.

[2]. Drabczyk, A., Kudłacik-Kramarczyk, S., Jamroży, M., & Krzan, M. (2024). Biomaterials in Drug Delivery: Advancements in Cancer and Diverse Therapies—Review. International Journal of Molecular Sciences, 25(6), 3126.

[3]. Yousefi Rizi, H. A., Shin, D. H., & Yousefi Rizi, S. (2022). Polymeric Nanoparticles in Cancer Chemotherapy: A Narrative Review. Iranian Journal of Public Health, 51(2), 226-239.

[4]. Zhang, Y., Chen, Q., Zhu, Y., Pei, M., Wang, K., Qu, X., … & Qin, H. (2022). Targeting inorganic nanoparticles to tumors using biological membrane‐coated technology. MedComm, 3(4), e192.

[5]. Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021). Engineering precision nanoparticles for drug delivery. Nature Reviews Drug Discovery, 20(2), 101-124.

[6]. Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine: progress, challenges and opportunities. Nature Reviews Cancer, 17(1), 20-37.

[7]. Barenholz, Y. (2012). Doxil®—the first FDA-approved nano-drug: lessons learned. Journal of Controlled Release, 160(2), 117-134.

[8]. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2(12), 751-760.

References

[3]. Yousefi Rizi, H. A., Shin, D. H., & Yousefi Rizi, S. (2022). Polymeric Nanoparticles in Cancer Chemotherapy: A Narrative Review. Iranian Journal of Public Health, 51(2), 226-239.

[4]. Zhang, Y., Chen, Q., Zhu, Y., Pei, M., Wang, K., Qu, X., … & Qin, H. (2022). Targeting inorganic nanoparticles to tumors using biological membrane‐coated technology. MedComm, 3(4), e192.

[6]. Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine: progress, challenges and opportunities. Nature Reviews Cancer, 17(1), 20-37.

[7]. Barenholz, Y. (2012). Doxil®—the first FDA-approved nano-drug: lessons learned. Journal of Controlled Release, 160(2), 117-134.

[8]. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2(12), 751-760.

Cite this article

Yang,H. (2025). From Bench to Bedside: Material Selection and Clinical Translation of Nanocarrier Systems for Anticancer Drug Delivery. Theoretical and Natural Science,147,55-65.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

About volume

Volume title: Proceedings of ICBioMed 2025 Symposium: AI for Healthcare: Advanced Medical Data Analytics and Smart Rehabilitation

ISBN: 978-1-80590-489-2(Print) / 978-1-80590-490-8(Online)

Editor: Alan Wang

Conference website: https://2025.icbiomed.org/auckland.html

Conference date: 17 October 2025

Series: Theoretical and Natural Science

Volume number: Vol.147

ISSN: 2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:

1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.

3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).